BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18507061)

  • 1. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers.
    Toth B; Nieuwland R; Liebhardt S; Ditsch N; Steinig K; Stieber P; Rank A; Göhring P; Thaler CJ; Friese K; Bauerfeind I
    Anticancer Res; 2008; 28(2A):1107-12. PubMed ID: 18507061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.
    Fu Y; Li H
    Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
    Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
    J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
    Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
    Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
    Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
    Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
    Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
    Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
    Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
    Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
    Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
    Chen C; Chen Q; Dong Y; Liu X
    Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tumor markers in southern Indian breast cancer patients.
    Porika M; Malotu N; Veldandi UK; Yadala N; Abbagani S
    Asian Pac J Cancer Prev; 2010; 11(1):157-9. PubMed ID: 20593949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.